To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The Potential Role of miR-126 as a Prognostic Biomarker in Renal Cell Carcinoma
Örebro University, School of Medical Sciences. Örebro University Hospital.ORCID iD: 0000-0001-5533-7899
2018 (English)Conference paper, Oral presentation with published abstract (Refereed)
Abstract [en]

Renal cell carcinoma (RCC) is the most common renal tumor, consisting of ~3% of all malignancies worldwide. The prognosis of RCC can vary widely, and detecting patients at risk for recurrence at an early stage could improve the outcome for the patient. The factors used in the clinics today cannot reliably predict the natural history of the disease, thus there is a need for finding new biomarkers that can aid in predicting patient outcome. Several studies indicate that miRNAs are potential candidates as prognostic biomarkers for patients suffering from RCC. The aim of this study was to validate the potential of miR-126 to predict prognosis in a Swedish cohort of RCC patients. Methods: The expression of miR-126 was measured using quantitative PCR (qPCR) in formalin-fixed paraffin-embedded (FFPE) tumor tissue from 116 patients diagnosed with RCC between 1987 and 2010. Results: miR-126 was found to be differentially expressed between malignant and adjacent benign tissue. The expression of miR-126 was also differentially expressed between tumor grades, and stages of RCC. We could furthermore show that in a univariate model, a low expression of miR-126 was associated with shorter time to recurrence of the disease. Conclusion: Our results indicate that miR-126 expression has a potential to be used as a prognostic biomarker for patients suffering from RCC. However, further studies are needed in order to confirm these results.

Place, publisher, year, edition, pages
2018.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-68670OAI: oai:DiVA.org:oru-68670DiVA, id: diva2:1244234
Conference
3rd International Cancer Study & Therapy Conference, Rome, Italy, May 2-14, 2018
Available from: 2018-08-31 Created: 2018-08-31 Last updated: 2020-12-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Carlsson, Jessica

Search in DiVA

By author/editor
Carlsson, Jessica
By organisation
School of Medical SciencesÖrebro University Hospital
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 68 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf